Trial · NCT03184870
Results by group762
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 762
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | 10 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | 8 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | 10 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | 11 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | 8 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | 7 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | 7 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | 11 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | 1 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | 2 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | 32 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | 32 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | 25 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | 35 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | 35 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | 31 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | 23 | Participants | ||
| Number of Participants Experiencing Adverse Events (AEs) | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO | 32 | Participants | ||
| Number of Participants Experiencing Serious Adverse Events (SAEs) | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | 5 | Participants | ||
| Number of Participants Experiencing Serious Adverse Events (SAEs) | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03184870/results